Description
We invite you to join us at the upcoming 14th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders. The groundbreaking series of Alzheimer's and Parkinson's Diseases Conferences attract international medical and scientific professionals worldwide. The Conference is at the forefront of unraveling the mechanisms and improving the treatment of Alzheimer's, Parkinson's and other related neurodegenerative diseases. AD/PDTM Conferences uniquely combine distinct neurodegenerative diseases in one setting and examine their similarities and differences; a strong focus is mechanisms of disease, prevention and therapy.
The forthcoming AD/PDTM meeting, in 2019 will take place in Lisbon, Portugal, one of the most classical cities in Europe.
The continuing success of the AD/PDTM meetings is the result of several key ingredients:
1. A high-quality scientific program covering most recent research, developments, and treatments, with emphasis on overlaps and congruent results among AD, PD and related neurological disorders.
2. A multidisciplinary mix of participants representing both clinical investigators and basic scientists; as well as both established investigators and young upcoming talents.
3. An International Scientific Advisory Board covering a broad range of expertise in AD, PD and related neurological disorders.
4. A concerted attempt to provide an ambiance at the Conference that encourages interaction, exchange of ideas and networking opportunities among all participants.
5. Travel grants and various awards to junior faculty, postdoctoral fellows, and graduate students, intended to encourage attendance by young scientists at the Conference.
The remarkable success of the series of AD/PDTM Conferences is evident from the progressive increases from one Conference to the next, in the number of participants, over 3,217 in Vienna in 2017, the number of countries represented, 66 in Vienna, and the ratio of individuals below the age of 35 to that of the rest of the group. At AD/PDTM 2019 in Lisbon we anticipate an attendance of more than 3500 participants.
The reason for this success is the uniqueness of the AD/PDTM meetings, their academic quality combined with the interactive and collegial environment. We believe that there is no other conference in the world that presents such a high level of science in a condensed manner on one hand, yet on the other hand, provides an enormously comfortable atmosphere in which to enjoy it all.
We invite you to join us at the 14th International Conference on AD and PD, and we hope to welcome you in the Spring of 2019, in beautiful Lisbon.
| Abraham Fisher, Ph.D. President |
Roger M. Nitsch, M.D. Executive Organizer |
Manfred Windisch, Ph.D. Executive Organizer |
Call for paper
Call for paper description
Abstracts must be submitted via this website. Faxed or emailed abstracts will not be considered.
Please read the submission rules before submitting an abstract.
-
Please note each participant may present a maximum of 5 abstracts. There is no limit to the amount of abstracts one person may submit.
The system will count the amount of presentations from all submissions and notify you if the person you would like to assign as presenter has reached the maximum 5 presentations.
Submitters and co-authors can be listed on as many abstracts as needed.
- The presenting author is required to ensure that all co-authors are aware of the content of the abstract before submission.
- The presenting author must be listed as the first author.
- Submitted abstracts should include non-published data.
- Abstracts previously presented will not be accepted.
- All abstracts should be submitted and presented in clear English with accurate grammar and spelling of a quality suitable for publication. If you need help, please arrange for the review of your abstract by a colleague who is a native English speaker, by a university specific publications office (or other similar facility) or by a copy editor, prior to submission.
- Please submit symbols as words.
- All abstracts accepted for presentation will be published on the Conference website prior to the Conference.
- You may submit more than 1 abstract. However, presenters that are accepted for oral presentation will be permitted to give only 1 oral presentation. Additional accepted abstracts will therefore be poster only.
- The abstracts of the Conference will be published online as a supplement to the Neurodegenerative Diseases Journal (NDD) published by S. Karger AG (details to be confirmed)
- Please note the submitting author will receive all correspondence about the abstract so we advise that the submitting author details that are entered are the same details as those of the presenting author.
-
Eligible candidates for Junior Faculty Awards are graduate students (PhD, MD) or junior scientists up to five years after the doctorate degree (PhD, MD.
-
Please ensure that if you are submitting an abstract to be considered for theJunior Faculty Award that you upload all relevant supporting documents via the link you will receive in the confirmation e-mail you receive once you final submit your abstract.
- Abstracts may not be edited/updated after final submission. You are welcome to bring an updated abstract onsite with you.
- Your abstract is not successfully submitted until you receive a confirmation e-mail after clicking the final submit button. If you do not receive a confirmation e-mail, please contact us.
Topics of submission
| Themes: | Topics: |
| Theme A: β-Amyloid Diseases |
A1.a. Disease Mechanisms, Pathophysiology: Abeta aggregation, protein misfolding |
| A1.b. Disease Mechanisms, Pathophysiology: Cell to cell transmission, spreading of pathology, prion-like | |
| A1.c. Disease Mechanisms, Pathophysiology: Inflammation | |
| A1.d. Disease Mechanisms, Pathophysiology: Synaptic plastcity & synapse pathology | |
| A1.e. Disease Mechanisms, Pathophysiology: Cellular signalling, kinases, phosphatases, calcium | |
| A1.f. Disease Mechanisms, Pathophysiology: Lysosomes, ubiquitin, proteasome, ER stress, chaperones | |
| A1.g. Disease Mechanisms, Pathophysiology: Mitochondrial dysfunction, oxidative damage | |
| A1.h. Disease Mechanisms, Pathophysiology: Lipids, lipoproteins and membrane trafficking | |
| A1.i. Disease Mechanisms, Pathophysiology: Microglia | |
| A1.j. Disease Mechanisms, Pathophysiology: Astroglia | |
| A1.k. Disease Mechanisms, Pathophysiology: Neurogenesis | |
| A1.l. Disease Mechanisms, Pathophysiology: Vasculature, microbleeds, hypertension, angiogenesis | |
| A1.m. Disease Mechanisms, Pathophysiology: Blood-brain barrier | |
| A1.n. Disease Mechanisms, Pathophysiology: Metabolism, insulin | |
| A1.o. Disease Mechanisms, Pathophysiology: Neural networks, plasticity | |
| A1.p. Disease Mechanisms, Pathophysiology: Transcriptional & translational regulation, micro RNAs | |
| A1.q. Disease Mechanisms, Pathophysiology: Autophagy, apoptosis, cell death | |
| A1.r. Disease Mechanisms, Pathophysiology: Aging | |
| A1.s. Disease Mechanisms, Pathophysiology: Microbiome | |
| A1.t. Disease Mechanisms, Pathophysiology: Other | |
| A2.a. Therapeutic Targets, Mechanisms for Treatment: Abeta, truncated & pGlu-Abeta | |
| A2.b. Therapeutic Targets, Mechanisms for Treatment: Immunotherapy | |
| A2.c. Therapeutic Targets, Mechanisms for Treatment: Secretases, proteases | |
| A2.d. Therapeutic Targets, Mechanisms for Treatment: Kinases, other enzymes | |
| A2.e. Therapeutic Targets, Mechanisms for Treatment: Neurotransmitters & receptor-based | |
| A2.f. Therapeutic Targets, Mechanisms for Treatment: ApoE & lipoprotein-based | |
| A2.g. Therapeutic Targets, Mechanisms for Treatment: Anti-inflammatory | |
| A2.h. Therapeutic Targets, Mechanisms for Treatment: Anti-oxidants | |
| A2.i. Therapeutic Targets, Mechanisms for Treatment: Neurotrophic, synaptic plasticity, repair, regenerative medicine | |
| A2.j. Therapeutic Targets, Mechanisms for Treatment: Protein aggregation, misfolding, chaperones | |
| A2.k. Therapeutic Targets, Mechanisms for Treatment: TREM2 | |
| A2.l. Therapeutic Targets, Mechanisms for Treatment: CD33 | |
| A2.m. Therapeutic Targets, Mechanisms for Treatment: Microglia | |
| A2.n. Therapeutic Targets, Mechanisms for Treatment: Astroglia | |
| A2.o. Therapeutic Targets, Mechanisms for Treatment: Gene therapy and gene editing | |
| A2.p. Therapeutic Targets, Mechanisms for Treatment: ASO and RNAi | |
| A2.q. Therapeutic Targets, Mechanisms for Treatment: neurogenesis and iPSC | |
| A2.r. Therapeutic Targets, Mechanisms for Treatment: Other | |
| A3.a. Drug Development, Clinical Trials: Immunotherapy | |
| A3.b. Drug Development, Clinical Trials: Immunomodulators | |
| A3.c. Drug Development, Clinical Trials: Amyloid clearance | |
| A3.d. Drug Development, Clinical Trials: Secretase inhibitors & modulators | |
| A3.e. Drug Development, Clinical Trials: Aggregation inhibitors | |
| A3.f. Drug Development, Clinical Trials: Neuroprotective & mitochondrial compounds | |
| A3.g. Drug Development, Clinical Trials: Neurotransmitter-based modulators | |
| A3.h. Drug Development, Clinical Trials: Receptor ligands | |
| A3.i. Drug Development, Clinical Trials: Mitochondrial drugs | |
| A3.j. Drug Development, Clinical Trials: Cell-based therapies | |
| A3.k. Drug Development, Clinical Trials: Transcranial magnetic stimulation | |
| A3.l. Drug Development, Clinical Trials: Medicinal chemistry approaches, drug repurposing | |
| A3.m. Drug Development, Clinical Trials: Personalized medicines | |
| A3.n. Drug Development, Clinical Trials: Regulatory aspects | |
| A3.o. Drug Development, Clinical Trials: Non-pharmacological interventions | |
| A3.p. Drug Development, Clinical Trials: Other | |
| A4.a. Imaging, Biomarkers, Diagnostics: Structural MRI, MR spectroscopy | |
| A4.b. Imaging, Biomarkers, Diagnostics: Functional MRI | |
| A4.c. Imaging, Biomarkers, Diagnostics: PET - amyloid | |
| A4.d. Imaging, Biomarkers, Diagnostics: PET - glucose | |
| A4.e. Imaging, Biomarkers, Diagnostics: PET - other | |
| A4.f. Imaging, Biomarkers, Diagnostics: SPECT | |
| A4.g. Imaging, Biomarkers, Diagnostics: Multimodal imaging | |
| A4.h. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers | |
| A4.i. Imaging, Biomarkers, Diagnostics: EEG, brain mapping, MEG | |
| A4.j. Imaging, Biomarkers, Diagnostics: Cognitive, psychometric & behavioral tests | |
| A4.k. Imaging, Biomarkers, Diagnostics: Other | |
| A5.a. Genetics, Epidemiology: Whole genome sequencing | |
| A5.b. Genetics, Epidemiology: Disease-causing mutations | |
| A5.c. Genetics, Epidemiology: GWAS, genetic associations, susceptibility & protective genes | |
| A5.e. Genetics, Epidemiology: Aging | |
| A5.f. Genetics, Epidemiology: Environmental risk factors | |
| A5.g. Genetics, Epidemiology: Metabolic and cardiovascular | |
| A5.h. Genetics, Epidemiology: Infectious and inflammation | |
| A5.i. Genetics, Epidemiology: Other | |
| A6.a. Cell, Molecular and Systems Biology: APP, APLP, Abeta | |
| A6.b. Cell, Molecular and Systems Biology: ApoE | |
| A6.c. Cell, Molecular and Systems Biology: Secretases | |
| A6.d. Cell, Molecular and Systems Biology: Growth factors, synaptic plasticity | |
| A6.e. Cell, Molecular and Systems Biology: GCPR, nicotinic, sigma-1 & other receptors | |
| A6.f. Cell, Molecular and Systems Biology: Network biology, connectome, protein-protein interations | |
| A6.g. Cell, Molecular and Systems Biology: Metabolomics, transcriptomics, lipidomics, proteomics | |
| A6.h. Cell, Molecular and Systems Biology: Epigenetics, histone modification, DNA methylation | |
| A6.i. Cell, Molecular and Systems Biology: Other | |
| A7.a. Animal Models: Transgenic rodents | |
| A7.b. Animal Models: Primates, naturally occuring models | |
| A7.c. Animal Models: Non-mamalian models | |
| A7.d. Animal Models: Optogenetics | |
| A7.e. Animal Models: Other | |
| Theme B: Taupathies |
B1.a. Disease Mechanisms, Pathophysiology: Tau aggregation, phophorylation, acetylation & modifications |
| B1.b. Disease Mechanisms, Pathophysiology: Cell to cell transmission, spreading of pathology, prion-like | |
| B1.c. Disease Mechanisms, Pathophysiology: Inflammation | |
| B1.d. Disease Mechanisms, Pathophysiology: Synapse pathology | |
| B1.e. Disease Mechanisms, Pathophysiology: Cellular signalling, kinases, phosphatases, calcium | |
| B1.f. Disease Mechanisms, Pathophysiology: Lysosomes, ubiquitin, proteasome, ER stress | |
| B1.g. Disease Mechanisms, Pathophysiology: Mitochondrial dysfunction, oxidative damage | |
| B1.h. Disease Mechanisms, Pathophysiology: Lipids, lipoproteins and membrane trafficking | |
| B1.i. Disease Mechanisms, Pathophysiology: Microglia | |
| B1.j. Disease Mechanisms, Pathophysiology: Astroglia | |
| B1.k. Disease Mechanisms, Pathophysiology: Neurogenesis | |
| B1.l. Disease Mechanisms, Pathophysiology: Vasculature, angiogenesis | |
| B1.m. Disease Mechanisms, Pathophysiology: Blood-brain barrier | |
| B1.n. Disease Mechanisms, Pathophysiology: Metabolism, insulin | |
| B1.o. Disease Mechanisms, Pathophysiology: Neural networks & plasticity | |
| B1.p. Disease Mechanisms, Pathophysiology: transcriptional & translational regulation, micro RNAs | |
| B1.q. Disease Mechanisms, Pathophysiology: Autophagy, apoptosis, cell death | |
| B1.r. Disease Mechanisms, Pathophysiology: Protein misfolding, chaperones | |
| B1.s. Disease Mechanisms, Pathophysiology: Aging | |
| B1.t. Disease Mechanisms, Pathophysiology: Microbiome | |
| B1.u. Disease Mechanisms, Pathophysiology: Other | |
| B2.a. Therapeutic Targets, Mechanisms for Treatment: Tau, phosphorylation, truncation | |
| B2.b. Therapeutic Targets, Mechanisms for Treatment: Immunotherapy | |
| B2.c. Therapeutic Targets, Mechanisms for Treatment: Kinases, phosphatases, other enzymes | |
| B2.d. Therapeutic Targets, Mechanisms for Treatment: Neurotransmitters & receptor-based | |
| B2.e. Therapeutic Targets, Mechanisms for Treatment: Anti-inflammatory | |
| B2.f. Therapeutic Targets, Mechanisms for Treatment: Anti-oxidants | |
| B2.g. Therapeutic Targets, Mechanisms for Treatment: Neurotrophic, synaptic plasticity, repair | |
| B2.h. Therapeutic Targets, Mechanisms for Treatment: Protein aggregation, NFT, misfolding, chaperones | |
| B2.i. Therapeutic Targets, Mechanisms for Treatment: Gene and RNAi therapy | |
| B2.j. Therapeutic Targets, Mechanisms for Treatment: Microglia | |
| b2.k. Therapeutic Targets, Mechanisms for Treatment: Astroglia | |
| B2.l. Therapeutic Targets, Mechanisms for Treatment: Adult neurogenesis | |
| B2.m. Therapeutic Targets, Mechanisms for Treatment: Other | |
| B3.a. Drug Development, Clinical Trials: Immunotherapy | |
| B3.b. Drug Development, Clinical Trials: Immunomodulators | |
| B3.c. Drug Development, Clinical Trials: tau clearance | |
| B3.d. Drug Development, Clinical Trials: Kinase inhibitors & phosphatase modulators | |
| B3.e. Drug Development, Clinical Trials: Aggregation inhibitors | |
| B3.f. Drug Development, Clinical Trials: Neuroprotective & mitochondrial compounds | |
| B3.g. Drug Development, Clinical Trials: Neurotransmitter-based modulators | |
| B3.h. Drug Development, Clinical Trials: Mitochondrial drugs | |
| B3.i. Drug Development, Clinical Trials: Cell-based therapies | |
| B3.j. Drug Development, Clinical Trials: Transcranial magnetic stimulation | |
| B3.k. Drug Development, Clinical Trials: Personalized medicines | |
| B3.l. Drug Development, Clinical Trials: Regulatory aspects | |
| B3.m. Drug Development, Clinical Trials: Medicinal chemistry approaches, drug repurposing | |
| B3.n. Drug Development, Clinical Trials: Non-pharmacological interventions | |
| B3.o. Drug Development, Clinical Trials: Other | |
| B4.a. Imaging, Biomarkers, Diagnostics: Structural MRI, MR spectroscopy | |
| B4.b. Imaging, Biomarkers, Diagnostics: Functional MRI | |
| B4.c. Imaging, Biomarkers, Diagnostics: PET - tau | |
| B4.d. Imaging, Biomarkers, Diagnostics: PET - glucose | |
| B4.e. Imaging, Biomarkers, Diagnostics: PET - other | |
| B4.f. Imaging, Biomarkers, Diagnostics: SPECT | |
| B4.g. Imaging, Biomarkers, Diagnostics: Multimodal imaging | |
| B4.h. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers | |
| B4.i. Imaging, Biomarkers, Diagnostics: EEG, brain mapping, MEG | |
| B4.j. Imaging, Biomarkers, Diagnostics: Cognitive, psychometric & behavioral tests | |
| B4.k. Imaging, Biomarkers, Diagnostics: Other | |
| B5.a. Genetics, Epidemiology: Whole genome sequencing | |
| B5.b. Genetics, Epidemiology: Disease-causing mutations | |
| B5.c. Genetics, Epidemiology: GWAS, genetic associations, susceptibility & protective genes | |
| B5.d. Genetics, Epidemiology: Aging | |
| B5.e. Genetics, Epidemiology: Environmental risk factors | |
| B5.f. Genetics, Epidemiology: Metabolic, cardiovascular, inflammation | |
| B5.g. Genetics, Epidemiology: Other | |
| B6.a. Cell, Molecular and Systems Biology: Tau, tau isoforms | |
| B6.b. Cell, Molecular and Systems Biology: Kinases, phosphatases | |
| B6.c. Cell, Molecular and Systems Biology: Posttranslational modifications | |
| B6.d. Cell, Molecular and Systems Biology: Growth factors, synaptic plasticity | |
| B6.e. Cell, Molecular and Systems Biology: GCPR, nicotinic, sigma-1, other receptors | |
| B6.f. Cell, Molecular and Systems Biology: Network biology, connectome, protein-protein interations | |
| B6.g. Cell, Molecular and Systems Biology: Metabolomics, transcriptomics, lipidomics, proteomics | |
| B6.h. Cell, Molecular and Systems Biology: Epigenetics, histone modification, DNA methylation | |
| B4.k. Cell, Molecular and Systems Biology: Other | |
| B7.a. Animal Models: Transgenic rodents | |
| B7.b. Animal Models: Primates, naturally occuring models | |
| B7.c. Animal Models: Non-mamalian models | |
| B7.d. Animal Models: Optogenetics | |
| B7.3. Animal Models: Other | |
| Theme C: α-Synucleinopathies |
C1.a. Disease Mechanisms, Pathophysiology: Α-synuclein aggregation |
| C1.b. Disease Mechanisms, Pathophysiology: LRKK2, parkin, PINK1, DJ-1 | |
| C1.c. Disease Mechanisms, Pathophysiology: Cell to cell transmission, spreading of pathology, prion-like | |
| C1.d. Disease Mechanisms, Pathophysiology: Autophagy, lysosomes, ubiquitin, proteasome | |
| C1.e. Disease Mechanisms, Pathophysiology: Lipids, lipoproteins and membrane trafficking | |
| C1.f. Disease Mechanisms, Pathophysiology: Inflammation | |
| C1.g. Disease Mechanisms, Pathophysiology: Microglia | |
| C1.h. Disease Mechanisms, Pathophysiology: Astroglia | |
| C1.i. Disease Mechanisms, Pathophysiology: Cellular signalling, kinases, phosphatases, calcium | |
| C1.i. Disease Mechanisms, Pathophysiology: Mitochondrial dysfunction, oxidative damage | |
| C1.j. Disease Mechanisms, Pathophysiology: Vasculature, angiogenesis, blood-brain barrier | |
| C1.k. Disease Mechanisms, Pathophysiology: Synapse pathology, neural networks, plasticity, neurogenesis | |
| C1.l. Disease Mechanisms, Pathophysiology: Transcriptional & translational regulation, micro RNAs | |
| C1.m. Disease Mechanisms, Pathophysiology: apoptosis, cell death | |
| C1.n. Disease Mechanisms, Pathophysiology: Protein aggregation, misfolding, chaperones | |
| C1.o. Disease Mechanisms, Pathophysiology: Metal ions | |
| C1.p. Disease Mechanisms, Pathophysiology: Modeling of disease progression | |
| C1.q. Disease Mechanisms, Pathophysiology: Other | |
| C2.a. Therapeutic Targets, Mechanisms for Treatment: Α-synuclein | |
| C2.b. Therapeutic Targets, Mechanisms for Treatment: Immunotherapy | |
| C2.c. Therapeutic Targets, Mechanisms for Treatment: Kinases, other enzymes | |
| C2.d. Therapeutic Targets, Mechanisms for Treatment: Dopamine, neurotransmitters | |
| C2.e. Therapeutic Targets, Mechanisms for Treatment: Cell transplantation | |
| C2.f. Therapeutic Targets, Mechanisms for Treatment: Deep brain stimulation | |
| C2.g. Therapeutic Targets, Mechanisms for Treatment: Anti-inflammatory, anti-oxidant | |
| C2.h. Therapeutic Targets, Mechanisms for Treatment: Microglia | |
| C2.i. Therapeutic Targets, Mechanisms for Treatment:Astroglia | |
| C2.j. Therapeutic Targets, Mechanisms for Treatment: Protein aggregation, misfolding, chaperones | |
| C2.k. Therapeutic Targets, Mechanisms for Treatment: Gene therapy and gene editing | |
| C2.l. Therapeutic Targets, Mechanisms for Treatment: ASO and RNAi | |
| C2.m. Therapeutic Targets, Mechanisms for Treatment: neurogenesis and iPSC | |
| C2.n. Therapeutic Targets, Mechanisms for Treatment: Other | |
| C3.a. Drug Development, Clinical Trials: Immunotherapy | |
| C3.b. Drug Development, Clinical Trials: Vitamins, antioxidants, neuroprotective compounds | |
| C3.c. Drug Development, Clinical Trials: Neurotransmitter- and receptor based modulators | |
| C3.d. Drug Development, Clinical Trials: Deep brain stimulation | |
| C3.e. Drug Development, Clinical Trials: Aggregation inhibitors | |
| C3.f. Drug Development, Clinical Trials: Enzyme modulators | |
| C3.g. Drug Development, Clinical Trials: Medicinal chemistry approaches, drug repurposing | |
| C3.h. Drug Development, Clinical Trials: Drug delivery systems | |
| C3.i. Drug Development, Clinical Trials: Non-pharmacological interventions, neurosurgery | |
| C3.j. Drug Development, Clinical Trials: Microbiome | |
| C3.k. Drug Development, Clinical Trials: Other | |
| C4.a. Imaging, Biomarkers, Diagnostics: Structural MRI, MR spectroscopy | |
| C4.b. Imaging, Biomarkers, Diagnostics: Functional MRI | |
| C4.c. Imaging, Biomarkers, Diagnostics: PET | |
| C4.d. Imaging, Biomarkers, Diagnostics: SPECT | |
| C4.e. Imaging, Biomarkers, Diagnostics: Multimodal imaging | |
| C4.f. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers | |
| C4.g. Imaging, Biomarkers, Diagnostics: EEG, brain mapping, MEG | |
| C4.h. Imaging, Biomarkers, Diagnostics: Cognitive, psychometric, behavioral and motor tests | |
| C4.i. Imaging, Biomarkers, Diagnostics: Microbiome | |
| C4.j. Imaging, Biomarkers, Diagnostics: Other | |
| C5.a. Genetics, Epidemiology: Whole genome sequencing | |
| C5.b. Genetics, Epidemiology: Disease-causing mutations | |
| C5.c. Genetics, Epidemiology: GWAS, genetic associations, susceptibility & protective genes | |
| C5.d. Genetics, Epidemiology: Aging | |
| C5.e. Genetics, Epidemiology: Environmental risk factors | |
| C5.f. Genetics, Epidemiology: Inflammation | |
| C5.g. Genetics, Epidemiology: Other | |
| C6.a. Cell, Molecular and Systems Biology: Α-synuclein | |
| C6.b. Cell, Molecular and Systems Biology: LRKK2, parkin, PINK1, DJ-1 and other PD realted genes | |
| C6.c. Cell, Molecular and Systems Biology: Growth factors, synaptic plasticity | |
| C6.d. Cell, Molecular and Systems Biology: GCPR, dopamine & other receptors | |
| C6.e. Cell, Molecular and Systems Biology: Network biology, connectome, protein-protein interations | |
| C6.f. Cell, Molecular and Systems Biology: Metabolomics, transcriptomics, lipidomics, proteomics | |
| C6.g. Cell, Molecular and Systems Biology: Epigenetics, histone modification, DNA methylation | |
| C6.h. Cell, Molecular and Systems Biology: Other | |
| C7.a. Animal Models: Transgenic rodents | |
| C7.b. Animal Models: Primates, naturally occuring models | |
| C7.c. Animal Models: Non-mamalian models | |
| C7.d. Animal Models: Optogenetics | |
| C7.e. Animal Models: Other | |
| Theme D: TDP43- and C9orf72-Related Diseases |
D1. Disease Mechanisms, Pathophysiology |
| D2. Therapeutic Targets, Mechanisms for Treatment | |
| D3. Drug Development, Clinical Trials | |
| D4. Imaging, Biomarkers, Diagnostics | |
| D5. Genetics, Epidemiology | |
| D6. Cell, Molecular and Systems Biology | |
| D7. Animal Models | |
| Theme E : Vascular Diseases |
E1. Disease Mechanisms, Pathophysiology |
| E2. Therapeutic Targets, Mechanisms for Treatment | |
| E3. Drug Development, Clinical Trials | |
| E4. Imaging, Biomarkers, Diagnostics | |
| E5. Genetics, Epidemiology | |
| E6. Cell, Molecular and Systems Biology | |
| E7. Animal Models | |
| Theme F: Prion Diseases |
F1. Disease Mechanisms, Pathophysiology |
| F2. Therapeutic Targets, Mechanisms for Treatment | |
| F3. Drug Development, Clinical Trials | |
| F4. Imaging, Biomarkers, Diagnostics | |
| F5. Genetics, Epidemiology | |
| F6. Cell, Molecular and Systems Biology | |
| F7. Animal Models | |
| Theme G: Huntington's and Other Neurodegenerative Diseases |
G1. Disease Mechanisms, Pathophysiology |
| G2. Therapeutic Targets, Mechanisms for Treatment | |
| G3. Drug Development, Clinical Trials | |
| G4. Imaging, Biomarkers, Diagnostics | |
| G5. Genetics, Epidemiology | |
| G6. Cell, Molecular and Systems Biology | |
| G7. Animal Models | |
| Theme H: Demyelinating Diseases |
H1. Disease Mechanisms, Pathophysiology |
| H2. Therapeutic Targets, Mechanisms for Treatment | |
| H3. Drug Development, Clinical Trials | |
| H4. Imaging, Biomarkers, Diagnostics | |
| H5. Genetics, Epidemiology | |
| H6. Cell, Molecular and Systems Biology | |
| H7. Animal Models | |
| Theme I: Lysosomal Storage Diseases |
I1. Disease Mechanisms, Pathophysiology |
| I2. Therapeutic Targets, Mechanisms for Treatment | |
| I3. Drug Development, Clinical Trials | |
| I4. Imaging, Biomarkers, Diagnostics | |
| I5. Genetics, Epidemiology | |
| I6. Cell, Molecular and Systems Biology | |
| I7. Animal Models | |
| Theme J: Psychiatric Symptoms in Neurodegenerative Diseases |
J1. Disease Mechanisms, Pathophysiology |
| J2. Therapeutic Targets, Mechanisms for Treatment | |
| J3. Drug Development, Clinical Trials | |
| J4. Imaging, Biomarkers, Diagnostics | |
| J5. Genetics, Epidemiology | |
| J6. Cell, Molecular and Systems Biology | |
| J7. Animal Models | |
| Theme K: Patient Care and Support |
K1.a. Dementia and Cognitive Dyfunction: Caregiver support |
| K1.b. Dementia and Cognitive Dyfunction: Mobile applications, social networks | |
| K1.c. Dementia and Cognitive Dyfunction: Cognitive training | |
| K1.d. Dementia and Cognitive Dyfunction: Exercise | |
| K1.e. Dementia and Cognitive Dyfunction: Support devices & monitoring | |
| K1.f. Dementia and Cognitive Dyfunction: Quality of life | |
| K1.g. Dementia and Cognitive Dyfunction: Functional foods | |
| K1.h. Dementia and Cognitive Dyfunction: Behavioral & psychiatric symptoms | |
| K1.i. Dementia and Cognitive Dyfunction: Fall prevention & patient protection | |
| K1.j. Dementia and Cognitive Dyfunction: Other | |
| K2.a. Movement Disorders: Caregiver support | |
| K2.b. Movement Disorders: Mobile applications, social networks | |
| K2.c. Movement Disorders: Motor coordination & exercise | |
| K2.d. Movement Disorders: Support devices & monitoring | |
| K2.e. Movement Disorders: Functional foods | |
| K2.f. Movement Disorders: Quality of life | |
| K2.g. Movement Disorders: Fall prevention & patient protection | |
| K2.g. Movement Disorders: Behavioral & psychiatric symptoms | |
| K2.h. Movement Disorders: Other |